IRIS
VIGNERI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.808
EU - Europa 6.912
AS - Asia 6.303
SA - Sud America 1.055
AF - Africa 758
Continente sconosciuto - Info sul continente non disponibili 437
OC - Oceania 12
AN - Antartide 1
Totale 27.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.354
SG - Singapore 2.976
RU - Federazione Russa 2.062
IT - Italia 1.878
CN - Cina 1.520
BR - Brasile 869
IE - Irlanda 771
UA - Ucraina 589
VN - Vietnam 480
IN - India 471
CI - Costa d'Avorio 381
CA - Canada 318
DE - Germania 312
FR - Francia 286
KR - Corea 221
SE - Svezia 200
BD - Bangladesh 184
GB - Regno Unito 178
NL - Olanda 165
NG - Nigeria 132
SN - Senegal 116
BE - Belgio 112
FI - Finlandia 91
MX - Messico 71
AR - Argentina 69
IQ - Iraq 63
PL - Polonia 61
JP - Giappone 57
ES - Italia 48
HK - Hong Kong 45
CZ - Repubblica Ceca 38
TR - Turchia 35
UZ - Uzbekistan 35
ZA - Sudafrica 33
IR - Iran 32
CO - Colombia 27
EC - Ecuador 27
VE - Venezuela 26
CH - Svizzera 25
BJ - Benin 24
AE - Emirati Arabi Uniti 22
PK - Pakistan 21
ID - Indonesia 20
KE - Kenya 20
SA - Arabia Saudita 19
AT - Austria 17
GR - Grecia 17
MA - Marocco 15
IL - Israele 13
JM - Giamaica 13
MY - Malesia 13
CL - Cile 12
CR - Costa Rica 12
LB - Libano 12
TT - Trinidad e Tobago 12
LT - Lituania 11
TN - Tunisia 11
AU - Australia 10
EG - Egitto 9
OM - Oman 9
PH - Filippine 9
AL - Albania 8
PY - Paraguay 8
RO - Romania 8
AZ - Azerbaigian 7
BG - Bulgaria 7
KZ - Kazakistan 7
RS - Serbia 7
SV - El Salvador 7
DZ - Algeria 6
JO - Giordania 6
UY - Uruguay 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
PE - Perù 5
PS - Palestinian Territory 5
EU - Europa 4
HU - Ungheria 4
NI - Nicaragua 4
NO - Norvegia 4
NP - Nepal 4
ET - Etiopia 3
GA - Gabon 3
KG - Kirghizistan 3
PR - Porto Rico 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
CG - Congo 2
GT - Guatemala 2
HR - Croazia 2
LK - Sri Lanka 2
MD - Moldavia 2
MM - Myanmar 2
MN - Mongolia 2
PT - Portogallo 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AM - Armenia 1
Totale 26.837
Salva come PNG Salva come JPEG
Città #
Dallas 1.855
Singapore 1.800
Santa Clara 1.431
Moscow 932
San Jose 842
Chandler 841
Dublin 770
Jacksonville 647
Ashburn 614
Chicago 547
Catania 453
Abidjan 381
Boardman 342
Kochi 337
Hefei 335
Council Bluffs 279
Los Angeles 257
Lauterbourg 227
Seoul 220
Beijing 212
Cambridge 207
Lawrence 203
Nanjing 200
Andover 193
New York 170
Toronto 169
Ho Chi Minh City 149
Grafing 134
Hanoi 117
Dakar 116
Des Moines 113
San Mateo 100
Civitanova Marche 98
Buffalo 97
Milan 91
Wilmington 88
São Paulo 83
Palermo 74
Rotterdam 65
Lagos 64
Munich 63
Orem 63
Rome 63
Abuja 60
Ottawa 56
Tokyo 56
San Giovanni la Punta 53
Nanchang 51
Wingene 50
Montreal 49
Seattle 48
Warsaw 48
Hebei 47
Shenyang 45
Bari 44
Lappeenranta 43
Chennai 42
Hong Kong 41
Brooklyn 40
Dong Ket 40
Saint Petersburg 38
Brussels 37
Houston 36
Bremen 34
Phoenix 33
Portland 33
Amsterdam 32
Poplar 32
The Dalles 32
Atlanta 31
Changsha 30
Columbus 30
Jiaxing 30
Rio de Janeiro 30
Boston 29
Baghdad 28
Brno 28
Denver 28
Mexico City 28
Falls Church 26
Johannesburg 26
London 26
Tianjin 26
Turku 25
Belo Horizonte 24
Cotonou 24
San Francisco 24
Manchester 23
Miami 23
Stockholm 23
Helsinki 22
Frankfurt am Main 21
Tashkent 20
Florence 19
Messina 19
Pune 19
Naples 18
Tehran 18
Brasília 17
Augusta 16
Totale 17.913
Salva come PNG Salva come JPEG
Nome #
148P The impact of chemotherapy relative dose intensity on pathological complete response and event-free survival in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy 273
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 255
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 241
A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas 232
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 229
Correlation between weight and Recurrence Score in a cohort of HR+ve/ HER2-ve early breast cancer patients: a retrospective analysis 222
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 214
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 214
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 197
Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny 185
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 182
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 176
Biomarkers and prognostic factors for malignant pleural mesothelioma 174
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 174
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 174
Anaplastic thyroid cancer in sicily: The role of environmental characteristics. 172
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 171
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 167
Comparative proteomic analysis of insulin receptor isoform A and B signaling 166
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 165
Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review 165
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 162
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 159
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part I: MR imaging with pathologic correlation and technical considerations 157
A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine 157
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 156
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 154
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 153
Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review 152
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA 152
Histopathologic and mr imaging appearance of spontaneous and radiation-induced necrosis in uveal melanomas: Initial results 150
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 148
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 148
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 148
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part II: treatment indications and complications 148
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 147
Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas 146
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 145
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 145
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 145
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 144
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery 144
New insights in thyroid cancer and p53 family proteins 143
Increased thyroid cancer incidence in volcanic areas: A role of increased heavy metals in the environment? 143
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 141
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 140
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 140
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells 139
Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma 139
Navigating the Nexus: HIV and Breast Cancer—A Critical Review 137
Heavy metals in the volcanic environment and thyroid cancer 137
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 137
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients 136
Immunoexpression of p62/SQSTM1/Sequestosome-1 in human primary and recurrent IDH1/2 wild-type glioblastoma: A pilot study 135
Heavy Metals in the Environment and Thyroid Cancer 135
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 135
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 133
Orbital metastasis from thyroid cancer: a case report and review of the literature 132
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 132
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 132
ENDOMETRIAL STROMAL TUMOR (SARCOMA) WITH LIMITED MIOMETRIAL INFILTRATION: A RARE CASE WITH PELVI-PERITONEAL METASTASES 132
Mr imaging–pathologic correlation of uveal melanomas undergoing secondary enucleation after proton beam radiotherapy 132
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer 132
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 131
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 131
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 131
Giant Paratesticular Liposarcoma: Molecular Characterization and Management Principles with a Review of the Literature 130
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 130
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 127
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy 127
Differences among young adults, adults and elderly chronic myeloid leukemia patients 127
The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach 126
Cerebellar liponeurocytoma: clinical, histopathological and molecular features of a series of three cases, including one recurrent tumor 126
Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression 125
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint 124
Early occurrence of a thyroid carcinoma in a patient who developed Graves’ disease after treatment for Hodgkin’s disease 124
BCR-ABL tyrosine kinase activity modulates survivin expression via PI3K/AKT 122
A new kid on the block: Sacituzumab govitecan for the treatment of breast cancer and other solid tumors 122
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 121
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 121
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 121
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 121
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 119
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 119
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 119
Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma 119
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data 117
BCR-ABL tyrosine kinase activity modulates Survivin expression in CML cells 116
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 115
Uncommon long-term survival in a patient with chronic myeloid leukemia 114
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 114
The optimal timing between neoadjuvant therapy and surgery of breast cancer: a brief systematic review of the literature 112
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer 112
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 112
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 111
Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases 110
Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis 110
Lipoblastoma-like tumor of the inguinal region: a close mimicker of myxoid liposarcoma 109
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 109
Late Breaking Abstract - Comparison of VATS debulking surgery and HITHOC vs VATS talc pleurodesis alone in malignant pleural mesothelioma: a pilot study 106
Totale 14.600
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.294
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.294
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.139 0 0 22 20 229 37 223 49 136 28 56 339
2022/20232.775 228 144 58 296 208 462 32 540 633 20 94 60
2023/20241.443 108 220 52 78 76 257 34 86 10 67 268 187
2024/20255.951 159 869 311 258 1.148 686 255 185 364 460 780 476
2025/202612.084 736 720 2.065 771 1.823 2.473 1.368 251 560 622 442 253
2026/2027851 337 510 4 0 0 0 0 0 0 0 0 0
Totale 27.286